Tobrex® Ointment
Tobramycin 0.3% · ophthalmic ointment
Antibiotic
Approved uses
Mild to moderate external infections of the eye and its adnexa caused by susceptible bacteria
Half-inch ribbon into the affected eye(s) 2 or 3 times per day (mild to moderate disease)
97% cured or improved after 10 days, comparable to gentamicin ointment.
Severe external ocular infection
Half-inch ribbon into the affected eye(s) every 3 to 4 hours until improvement, then reduce frequency before discontinuing
Contraindications
Known hypersensitivity to tobramycin or any component of the formulation.
Ophthalmic ointment, 3.5 g aluminum tube, 0.3% (3 mg/g)
Water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens. In vitro activity spans staphylococci (including penicillin-resistant strains), some streptococci, Pseudomonas aeruginosa and other gram-negative organisms, and in some cases microorganisms resistant to gentamicin retain susceptibility to tobramycin. Aminoglycosides inhibit bacterial protein synthesis by binding to the 30S subunit, which blocks the initiation complex.
Warnings & Precautions
- Not for injection into the eye: Topical ophthalmic formulation only.
- Aminoglycoside hypersensitivity: Sensitivity to topically applied aminoglycosides may occur in some patients, and severity may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions; discontinue use if a sensitivity reaction occurs.
- Aminoglycoside cross-sensitivity: Cross-sensitivity to other aminoglycoside antibiotics may occur; discontinue and institute appropriate therapy if hypersensitivity develops.
- Superinfection: Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi; start appropriate therapy if superinfection occurs.
- Corneal wound healing: Ophthalmic ointments may retard corneal wound healing.
- Neurotoxicity, ototoxicity and nephrotoxicity: These have occurred in patients receiving systemic aminoglycoside therapy, and aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease.
- Contact lens wear: Not advised while signs and symptoms of ocular infection are present.
- Tube tip contamination: Do not touch the tube tip to any surface, as this may contaminate the ointment.
- Damaged carton seals: Do not use the product if the imprinted carton seals have been damaged or removed.
- Corneal epithelial toxicity: In a rabbit wound-healing study of eight topical antibiotic solutions, tobramycin was among the most toxic; the study tested solutions and did not test an ointment vehicle, and the authors concluded that not all antibiotics should be considered innocuous when used in the treatment of epithelial defects.
Common Side Effects
The most frequent adverse reactions are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema, and these reactions occur in less than three of 100 patients treated. Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.
Pregnancy: Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus; there are no adequate and well-controlled studies in pregnant women, and because animal studies are not always predictive of human response, use during pregnancy only if clearly needed.
Lactation: Because of the potential for adverse reactions in nursing infants, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Not established below age 2 months.